RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $5.29 Average PT from Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given a consensus recommendation of “Hold” by the nine brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $5.29.

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company dropped their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Finally, HC Wainwright raised RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Thursday, December 26th.

RAPT Therapeutics Stock Down 2.5 %

NASDAQ:RAPT opened at $1.15 on Friday. The firm’s fifty day simple moving average is $1.29 and its 200 day simple moving average is $1.62. The stock has a market cap of $40.20 million, a P/E ratio of -0.42 and a beta of 0.03. RAPT Therapeutics has a twelve month low of $0.79 and a twelve month high of $10.05.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Picton Mahoney Asset Management grew its stake in shares of RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after acquiring an additional 14,697 shares during the last quarter. JPMorgan Chase & Co. grew its position in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the last quarter. Readystate Asset Management LP bought a new stake in RAPT Therapeutics during the 3rd quarter valued at about $36,000. Barclays PLC increased its stake in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after purchasing an additional 29,195 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in RAPT Therapeutics in the fourth quarter worth about $63,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.